Shares of biotech firm BridgeBio Pharma (BBIO) have been trending down in the past year, with a big decline recently. However, one trader sees a rebound in shares in the weeks ahead.
That’s based on the January $75 call options. With 50 days until expiration, over 11,795 contracts traded against a prior open interest of 119, for a 100-fold surge in volume. The buyer of the calls paid $2.22 to make the trade.
Shares recently traded around $40, so the $75 calls would require shares to rise at least $35, or 87 percent in the next 50 days. That would put shares on par with their 52-week high, but such a move would require some sort of catalyst to best play out.
- The Hidden Trap Most Investors Don't Even Know They're In
The past 12 years have been a great time to be an investor. Unfortunately, the same forces that helped propel the market upwards, have also placed investors in a hidden wealth-destroying trap.
The sad part is most investors don't even realize the situation they're in...leaving their portfolios vulnerable to a market plunge that could wipe out years of hard work.
That's why I've put together a critical presentation detailing everything you need to know about this quiet "trap" - and how you can protect yourself against its destructive aftermath.
As an early-stage biotech company working on breakthrough treatments, the company doesn’t make money and currently sits on big losses. However, a breakthrough could lead to a massive move higher in shares, and the possibility of a buyout from a larger pharma company.
Action to take: This trade could play out well on a year-end market rally, or some unexpected good news for the company. That makes it potentially interesting. Investors could also buy shares here and sell covered calls, given the massive premiums available.
For traders, the option could pay out huge in the weeks ahead, or could end up bleeding out. Those who buy should look for a short-term profit and look to close out the trade early to take advantage of this particularly unusual options buy here.
Disclosure: The author of this article has no position in the company mentioned here, but may trade after the next 72 hours. The author receives no compensation from any of the companies mentioned in this article.